We examined binding to excitatory amino acid and inhibitory amino acid receptors in frozen hippocampal sections prepared from surgical specimens resected from 8 individuals with medically refractory temporal lobe epilepsy. The excitatory receptors studied included N-methyl-D-aspartate (NMDA), strychnine-insensitive glycine, phencyclidine, and quisqualate. The inhibitory receptors studied were gamma-aminobutyric acid type A (GABA,) and benzodiazepine. Excitatory and inhibitory amino acid receptor binding were differentially altered in the patients with temporal lobe epilepsy in comparison to 8 age-comparable autopsy control subjects, and changes in receptor binding were regionally selective in four areas. Binding to phencyclidine receptors associated with the NMDA channel was reduced by 35 to 70% in all regions in the hippocampi of the patients. In contrast, binding to the NMDA recognition site and its associated glycine modulatory site was elevated by 20 to 110% in the cornu ammonis (CA) 1 area and dentate gyrus of the hippocampus of the patients. Binding to these sites was unaffected in area CA4. Binding to the quisqualate-type excitatory amino acid receptor was unchanged in all regions except the stratum lacunosum moleculare CA1, where it was increased by 63%. GABA, and benzodiazepine receptor binding was reduced by 20 to 60% in CA1 and CA4, but unchanged in dentate gyrus. The data indicate that excitatory and inhibitory amino acid receptors are altered in the hippocampus of patients with temporal lobe epilepsy.
epilepsy: GABA type A (GABAA) receptor antagonists are potent convulsants and GABAergic markers are selectively reduced in temporal lobe epilepsy (TLE) 11-81. Excitatory amino acid (EAA) neurotransmitters such as glutamate and aspartate also may contribute to epileptic seizures and to central nervous system (CNS) The current study is based on the hypothesis that binding to EAA and inhibitory amino acid (IAA) neurotransmitter receptors may be altered in epileptic brain tissue of patients with TLE. We measured binding to receptors associated with the N-methy1-Daspartate (NMDA) receptodchannel complex, the quisqualate-type EAA receptors, and the GABAAbenzodiazepine complex IAA-type receptors in hippo- campal tissue resected from patients with medically refractory TLE and from comparably aged postmortem control specimens. The regional distribution of EAA and 1AA receptors in brain can be imaged and studied quantitatively by labeling each receptor with a tritiated ligand under conditions selective for each receptor type. The NMDAtype EAA receptodchannel complex is comprised of several regulatory binding sites (Fig 1) [38}. The NMDA recognition site can be selectively labeled, under appropriate conditions, with E3H]glutamate. The associated glycine modulatory site can be measured with C3H]glycine. The tritiated thienyl derivative of phencyclidine (TCP) selectively labels a binding site located within the NMDA receptor-associated ionophore. The quisqualate-subtype of EAA receptors can be measured with X3H]glutamate under selective conditions. The modulatory receptors comprising the GABA, receptor/ionophore complex can be measured with [3H]muscimol to label the GABA, recognition site and [3H}flunitrazepam to label the associated benzodiazepine site [3C)].
Materials and Methods
We studied 8 patients (4 males and 4 females) with medically refractory TLE whose seizure focus orlginated unilaterally ( Table 1) . The anterior 2 cm of the hippocampus was resected from these patients. Control hippocampus was obtained at autopsy from 8 subjects (4 males and 4 females) who had no reported history of neurological or psychiatric disease (mean age ? standard error of mean, 46 f 5 years; postmortem delay, 11 +-2 hours). Hippocampal tissue was examined by a neuropathologisr (P. E. M.) to determine an anatomical diagnosis, and neuronal loss was rated qualitatively. 
Materials

NMDA Recognition Site Binding
Regionally selective increases in binding to the NMDA recognition site were observed in the surgical hippocampal specimens compared to autopsy control brains ( 
Glycine Modalatory Site Binding
Selective laminar changes in E3Hfglycine binding were observed in the CA1 hippocampal subfield (see Table   2 and Fig 3) . In the TLE group, glycine modulatory site binding was significantly increased in stratum lacunosum moleculare but the level of binding in stratum pyramidale was equivalent to the level in autopsy control subjects. Binding in stratum moleculare in the dentate gyrus of TLE specimens was significantly elevated relative to binding in autopsy control subjects. In contrast, equivalent binding densities were observed in hippocampal subfield CA4 of TLE and control groups. The variation in {3H)glycine binding in both TLE and autopsy groups was greater than for any of the other binding assays and the degree of variation in the TLE group was especially pronounced. In fact, { 'Hfglycine binding densities in several patients with TLE were below the corresponding mean binding densities of the autopsy control subjects. 
Quisquulute-Type Receptor Binding
E3H1Glutamate binding to quisqualate-preferring receptors in stratum lacunosum moleculare of CA1 was significantly elevated in patients with TLE, compared with autopsy specimens (see Table 2 and Fig 3) . A similar trend was observed in stratum pyramidale of CA1, but the results were not statistically significant. However, equivalent binding densities were observed between specimens from patients with TLE and autopsy control subjects in the CA4 subfield and in stratum moleculare of the dentate gyrus. Interspecimen variation in binding densities was greatest in the TLE group, compared with the autopsy group.
GABAA Receptm Binding
The changes in IAA receptor binding in the hippocampus of patients with TLE were different from those in EAA binding (Figs 5 and 6; see Table 2 ). GABA, receptor binding was significantly reduced in both lami- Benzodiazepine Receptor Binding
TLE Patient
The regional changes in benzodiazepine receptor binding between and autopsy groups Paralleled the regional changes in GABAA receptor binding (see Ta- receptors was significantly reduced in stratum pyramidale of CA1 ( -29%) with a similar trend in stratum lacunosum moleculare of CA1. Binding densities were similar between groups in stratum moleculare of the dentate gyrus. A significant decrease in binding was observed in TLE CA4 subfield (-45%), compared to autopsy controls. The variability in binding between specimens was similar in TLE and control groups.
Discussion
We examined the hypothesis that EAA and IAA neurotransmitter receptor binding are altered in hippocampal tissue removed from patients with TLE. The hippocampal tissue examined in these studies contained pathological evidence of neuronal loss but not advanced mesial temporal sclerosis. Using quantitative receptor autoradiography, we found that EAA and IAA receptor binding were differentially altered in the hippocampus of patients with TLE, compared with autopsy control subjects. The observation that binding to IAA (GABA, and benzodiazepine) receptors was reduced is consistent with previous observations 141. Similarly, the reduction in binding to the PCP receptor site located within the excitatory NMDA receptor channel was reported in a recent preliminary communication {48). The novel observation made in this study is that the density of NMDA-type EAA receptor sites and glycine modulatory sites was increased in the same tissue in which binding to the PCP channel receptor was reduced. Thus, we found two possible neurotransmitter receptor alterations that could contribute to enhanced neuronal excitability: a reduction in IAA receptor binding and an increase in the ratio of NMDA and glycine-type EAA receptors to PCP-type receptors within the NMDA receptor-operated channel. Although this is the first report of an increase in the ratio of NMDA receptors to PCP receptors in hippocampus from patients with TLE, a similar alteration in the NMDA receptorlchannel complex was observed in animal experiments, described below [49, 503 . This change could contribute to enhanced vulnerability of the TLE hippocampus to progressive neuronal injury. The experimental methods and design of this study have some limitations. Both the small number of specimens and the inherent problems of neuropathological variability associated with studies of chronic neurologi-cal brain disorders limit the interpretation of the data. Because of the relatively small number of specimens per group, the effects of possible confounding variables such as the effects of postmortem delay on receptor binding in autopsy control specimens or the effects of chronic medication on receptor binding in patients with TLE could not be directly determined. Some evidence suggests that effects of postmortem delay do not substantdly alter the results. A previous study with a larger number of autopsy specimens demonstrated no correlation between the postmortem delay period (0 to 16 hours) and the density of EAA and IAA receptor binding [5 l}. Also, the EAA and IAA receptor binding changes observed in our study were in opposite directions and were regionally selective. This argues against a generalized effect of postmortem delay.
The greater mean age of autopsy control subjects compared with patients with TLE may contribute to the apparent elevation of receptor binding in TLE patients since in a previous study receptor binding densities tended to decrease up to 10% per decade in humans [5 11. Although these age-related differences may contribute to the observed changes, they cannot exp h n the entire increase in NMDA and glycine receptor binding in patients with TLE (50 to 100% increase) or the decreased binding to PCP receptors and GABA, or benzodiazepine receptors. The effects of medications may be confounding factors. Rinsing tissue sections prior to receptor labeling should remove perioperative or chronic anticonvulsant medications from the tissue of patients with TLE. Only 1 patient received a medication (morphine) that directly alters EAA and IAA receptor binding 1521. It is likely, however, that chronic anticonvulsant treatment contributed to the changes in receptor binding. Although none of the patients received anticonvulsant compounds whose site of action is at EAA or IAA receptors (except one who received primidone in combination therapy), chronic treatment may indirectly cause regulatory changes in these receptors. Although there is no experimental evidence to support this idea, the effects of chronic anticonvulsant treatment cannot be ruled out.
Another problem was the limited amount of hippocampal tissue avilable from patients with TLE. This made it impossible to perform detailed kinetic studies to assess whether the changes in equilibrium binding represented changes in receptor affinity or alterations in receptor numbers. In addition, the severity of regional neuronal loss in TLE specimens could not be reliably assessed in the frozen tissue sections. It is unlikely that differences between groups in endogenous neurotransmitters and neuromodulations that bind to EAA and IAA receptors could account for the observed changes in receptor binding since the tissue was prerinsed prior to receptor labeling under conditions that have been demonstrated to minimize potential differences in residual endogenous compounds. However, the binding could reflect the presence of very adhesive molecules such as polyamines. If this is the case, our in vitro observations could reflect physiologically significant alterations in the state of receptors in living tissue.
NMDA Recognition Site Binding
The pattern of NMDA recognition site binding observed in autopsy control specimens was similar to the pattern of binding observed in previous studies of human and nonhuman primate hippocampus [5 3-55}.
The regionally selective elevation of NMDA receptor binding within the CA1 subfield in stratum lacunosum moleculare and stratum pyramidale in TLE specimens corresponds to the hippocampal fields that receive the majority of EAA neurotransmitter inputs C141. The enhanced binding in TLE specimens compared to autopsy controls can be related to several mechanisms or combination of mechanisms. The apparent increase in NMDA receptor binding in patients with TLE may represent a selective loss of these receptors in the autopsy control specimens as a result of postmortem delay; however, this seems unlikely based on previous studies {5 1, 541. Alternatively, the enhanced binding may reflect regulatory changes secondary to altered neuronal activity, neuronal injury, adaptive reorganization of neuronal circuits, and/or chronic anticonvulsant treatment. Studies in experimental animals demonstrated that excitotoxic injury or abnormal functional activity in the hippocampus is associated with axonal sprouting and synaptic rearrangement [ 56-58}, and such synaptic rearrangements appear to occur in the hippocampus of patients with TLE C24, 59-61).
Whether these rearrangements are associated with an increase in NMDA receptor binding is not known. We found in a series of animal experiments that the nunber of NMDA receptor (recognition) sites increases rapidly by as much as 100% in response to treatment with drugs that block the NMDA-operated channel C49, 621.
Previous studies of NMDA receptor (recognition site) binding in human brain tissue from patients with epilepsy yielded conflicting results. NMDA receptor binding was elevated in two preliminary reports of NMDA receptor binding in patients with TIE. In one study, the maximal amount of ligand bound to the NMDA receptor binding was increased 2.5-fold in homogenates prepared from the epileptic focus in temporal Cortex compared to nonepileptic temporal cortex of patients with TLE [63}. In a second study, NMDA receptor binding was increased in the entorhind Cortex of TLE specimens compared to autopsy controls, as determined by quantitative receptor autoradiography [64] . Two other preliminary studies suggested that the NMDA recognition site binding is reduced in the hippocampus of patients with TLE. Hosford and colleagues {48] reported reduced NMDA-sensitive
[3H]glutamate binding in the CA3 subfield of patients with TLE from Ammon's horn sclerosis. In the second study {64), reductions in NMDA receptor binding were reported in the CAI, CA3, and CA4 hippocmpal subfields of patients with TLE from Ammon's horn sclerosis. The differences in results may reflect the severity of the neuropathology in the patients examined.
In contrast to the extensive neuronal loss in TLE specimens (i.e., Ammon's horn sclerosis) examined in the studies reporting NMDA receptor loss [48, 641 , the severity of pathology in our study was not as marked and none of our patients had Ammon's horn sclerosis.
Three of the 8 TLE specimens in our study contained low-grade gliomas.
Glycine Modtllatoy Site Binding
Previous studies of EAA receptor binding in TLE did not examine strychnine-insensitive {3H)glycine binding. The distribution of glycine modulatory site binding paralleled the distribution of NMDA recognition site binding in the hippocampus of autopsy control specimens, which is consistent with previous reports of colocalization of these receptors in human brain {65]. The regionally selective receptor binding changes observed in the hippocampus of patients with TLE paralleled, in general, the increases in NMDA recognition site binding. One exception was in stratum pyramidale of CA1, where only binding to the NMDA recognition site was elevated. The coordinate changes in these two binding sites are consistent with the idea that these two sites are components of the same receptor/channel complex (see Fig 1) . The results suggest that these two sites are simultaneously upregulated in the hippocampus of patients with TLE despite neuronal injury and cell loss.
Phencyclidine Receptor (Channel Site) Binding
The topography of C3H}TCP binding in autopsy control specimens was similar to the pattern of binding to the other two components of the NMDA receptor complex (NMDA and glycine receptors), which is consistent with the idea that these receptors comprise a receptor complex (see Fig 1) . The distribution of C3H]TCP binding was similar to the pattern described in previous reports on human hippocampus [66, 67) .
Reduced [?H)TCP binding w a found in all four hippocampal regions of patients with TLE compared to control subjects, in contrast to the more selective regional changes found in binding to NMDA and glycine sites. The same factors already mentioned (anticonvulsant treatment, neuronal cell loss and synaptic reorganization, receptor downregulation, and postmortem autolysis in control specimens) could have contributed to these changes. A previous study suggested that postmortem autolysis does not contribute to 
Qtlisqgalate-Type Receptor Binding
The regional distribution of quisqualate receptor binding in the hippocampus of control specimens was similar to the pattern described previously {53). The moderate elevation or maintenance of quisqualate receptor binding in the hippocampus of patients with TLE de-spite cell loss suggests that these sites are preserved or possibly upregulated in TLE. Interpretation of these data has the same limitations as that of the data concerning NMDA receptor binding. These data are consistent with findings in several preliminary reports of increased quisqualate receptor binding in hippocampus from patients with epilepsy. In one preliminary study of patients with TLE who had Ammon's horn sclerosis, there was significantly increased quisqualate receptor binding in stratum moleculare of the dentate gyrus and maintained binding in other hippocampal subfields despite extensive cell loss r48). In a second preliminary study, [3H)a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) binding to a subtype of quisqualate receptors was enhanced in entorhind cortex, maintained in stratum moleculare of the dentate gyrus, and reduced in CA1, CA3, and CA4 in the context of marked cell loss in the hippocampus of patients with TLE and with Ammon's horn sclerosis [64) .
GABA, and Benzodiazepine Receptor Binding
The regionally selective reductions in GABA, and benzodiazepine receptor binding found in patients with TLE are consistent with previous reports of reductions in GABAergic synaptic markers and selective injury and loss of hippocampal neurons 14, [22] [23] [24] [25] . Some studies demonstrated no alteration in GABAA and benzodiazepine receptor binding in patients with TLE or other forms of epilepsy 163, 76). It is possible that the reduction of GABAA and benzodiazepine binding in our study may reflect secondary downregulation resulting from neuronal injury or chronic anticonvulsant therapy. The relative contribution of neuronal loss to the decrease in GABA, and benzodiazepine receptor binding in specimens from patients with TLE is not addressed by this study. It is unclear from this study whether the trend for a greater reduction in benzodiazepine receptor binding than GABAA receptor binding in patients with TLE represents differential receptor regulation or an artifact of the binding assays.
Possible ImpEications of Altered Excitatouy and Inhibitory Amino Acid Receptor Bindivzg
The increased NMDA and glycine receptor binding and reduced IAA receptor binding observed in TLE specimens could predispose the hippocampus to neuronal hyperexcitability and possibly promote further seizures and neuronal injury. NMDA receptor activation is involved in burst discharges in hippocampal neurons [35, [77] [78] [79] [80] . Sustained bursting may result in excessive calcium entry and cytotoxicity [ 11, 12, [81] [82] [83] . Excitotoxic injury in the hippocampus is associated with axonal sprouting and synaptic rearrangement [56, 57) and these processes may be regulated by EAA receptor activation [84] . Such synaptic rearrangements are likely to occur in TLE [24, [59] [60] [61] . The increased binding to NMDA and glycine modulatory receptors in TLE may be related to an adaptive regulatory response to neuronal injury. In experimental paradigms, an increase in the ratio of NMDA receptors to PCP receptors is associated with an increase in susceptibility to neuronai damage from intracerebral injections of the excitotoxic glutamate analogue NMDA 1497. If this occurs in humans, it could contribute to the development of an epileptogenic focus over time. This could be an ongoing, cycling process involving neuronal injury and adaptive synaptic reorganization r23, 24, [56] [57] [58] [59] [60] [61] 
